why choose us

First received: March 11, 2023

Clinical Trial: Repurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative Colitis

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Inflammatory Bowel Diseases

Study Type: INTERVENTIONAL


Official Title: Repurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative Colitis

Brief Summary: Fibrates, specific pharmacological agonists of PPAR?, have been widely used to treat hypercholesterolemia and hypertriglyceridemia. Apart from their metabolic action, anti-inflammatory properties of fibrates have been described, including inhibition of NF-kappa B signaling and pro-inflammatory cytokine production.4 Fenofibrate, an important peroxisome proliferator-activated receptor-a (PPAR- ?) agonist, is widely used in clinical as a triglyceride (TG)-lowering agent

Read more